Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
4500 participants
INTERVENTIONAL
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- High blood pressure is one of the most important risk factors to cardiovascular diseases (CVDs). Reducing population blood pressure can control CVD incidence and lower mortality effectively. Much research has proven that adjusting for Na and K intake level can reduce blood pressure. According to the China Salt Substitute Study, the systolic blood pressure of intervention group which used salt substitute is 5.4 mmHg lower than that of control group. Life expectancy in Tibet is 67 years old. It is estimated that the use of salt substitute among population in Tibet can reduce total mortality in Tibet by 20%. China Salt Substitute Study in Tibet (CSSS-Tibet), found that salt substitute is effective in lowering both systolic and diastolic blood pressure and offers a simple, low-cost approach for hypertension control among Tibetans in China (unpublished results). However, the study focused on hypertensive patients, the effectiveness of hypertension control by providing free salt substitute to the entire population remains unknown, and a large-scale trial is needed.
2. Objectives
\- Primary objective is to observe the effect of providing salt substitute on population blood pressure in Tibet. Secondary objective is to observe the effect of such intervention on population mortality, cardiovascular mortality and life expectancy. In addition, the data collected from high-risk population (sub-group) in the study will be used in China Salt Substitute and Stroke Study (SSaSS). Also, serum cholesterol and random blood glucose of people over 60 in Tibet will be collected.
3. Method
* The study is a open, cluster-randomized, controlled trial.
* 30 villages with 15 to 35 households each and a distance of at least five kilometers in between will be selected from Damxung county and Maizhokunggar county. The two counties have an average altitude of over 4000 meters in Tibet Autonomous Region.
* All selected villages will be randomly assigned to intervention group or control group on a 1:1 ratio.
* All household in the selected villages will be recruited if they meet the eligibility criteria. Approximately 4,500 participants will be enrolled
* Intervention group receives free salt substitute. Control group will continue to buy their own normal salt. Both group will receive the same health education on salt reduction.
4. Outcome - Primary outcome is blood pressure. Secondary outcomes include total mortality, cardiovascular disease mortality, life expectancy, serum cholesterol level of people over 60, and random blood glucose level of people over 60.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
China Salt Substitute Study in Tibet
NCT01429246
Impact of Self-monitoring of Salt Intake by Salt Meter in Hypertensive Patients
NCT04286802
Activating Media for Salt Reduction
NCT03074851
Community Health Worker Led Hypertension Prevention and Control
NCT06230835
Impact of Yoga on Blood Pressure, Quality of Life and Stress in Patients With Hypertension
NCT01984593
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Salt Substitute
salt substitute
salt substitute
Free salt substitute provided
Control
Participants continue to buy salt at their own expense
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
salt substitute
Free salt substitute provided
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any member in the family is using a potassium supplement
* Any member in the family has serious renal impairment
* Any member in the family over 18 could not sign informed consent
* Life expectancy of any member in the family is shorter than 6 months in doctor's opinion
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The George Institute for Global Health at PUHSC
UNKNOWN
The George Institute for Global Health, Australia
OTHER
Science and Technology Department of Ningxia
UNKNOWN
People's Hospital of Tibet
UNKNOWN
People's Hospital of Maizhokunggar
UNKNOWN
Tibet University
OTHER
Peking University
OTHER
People's Hospital of Damxung County, Tibet
UNKNOWN
Beijing Jishuitan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xingshan Zhao
Vice-president; Director, Department of Cardiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xingshan Zhao, M.D.
Role: PRINCIPAL_INVESTIGATOR
Beijing Jishuitan Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Damxung, Tibet, China
Maizhokunggar, Tibet, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013BAI05B04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.